Nocturnal hypoxia: An unrecognised risk factor for neovascular age-related macular degeneration
Read MoreNocturnal hypoxia: An unrecognised risk factor for neovascular age-related macular degeneration
Read MoreMacular vascular disease: software standardisation and data harmonisation to accelerate the development of new imaging biomarkers and therapies
Read MoreNext-generation gene therapy for Stargardt Disease: Enhanced AAV-mediated ABCA4 delivery to restore vision
Read MoreMDFA is Australia’s largest source of research funding in the field of macular disease outside of government.
Read MoreMacular Disease Foundation Australia today announced it has awarded more than $1 million to eight
Read MoreMacular Disease Foundation Australia (MDFA) has announced the launch of its inaugural MDFA 25th Anniversary Award
Read MoreMacular Disease Foundation Australia (MDFA) has launched its new Research Impact Report, which showcases the groundbreaking projects our organisation has funded to help reduce the impact of macular disease.
Read MoreThe launch of the new Elisabeth Macdonald Memorial Award coincides with World Sight Day (9 October 2025) and marks the beginning of MDFA’s 25th anniversary year.
Read MoreAffording sight-saving treatments and support is a challenge faced by many people in the macular disease community.
Read More